MedTrace Logo

Adverse Events Related to Low Dose Atropine

NCT05683535 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 148

Last updated 2023-04-25

No results posted yet for this study

Summary

Progressive myopia can lead to severe vision loss and is associated with retinal detachment, glaucoma, and other comorbidities. Several studies have shown that off-label, low-dose atropine eye drops slow the progression of myopia. Many eye care providers are now prescribing off-label atropine eye drops for their myopic patients, with the prescribed concentrations varying amongst providers.

The purpose of this study is to determine if low-dose atropine eyedrops used daily, cause adverse effects to the eyes. Patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops obtained from compounding pharmacies will be assessed for associated adverse effects.

Conditions

  • Myopia, Progressive

Interventions

DRUG

Atropine Sulfate

0.01%, 0.03%, or 0.05% atropine eye drops made from compounding pharmacies.

Sponsors & Collaborators

  • Scripps Health

    lead OTHER

Principal Investigators

  • Gregory Ostrow, MD · Scripps Health

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-19
Primary Completion
2023-01-09
Completion
2023-01-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05683535 on ClinicalTrials.gov